This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.
Topic Depression
Country United States of America
Visit trial
Status
Active, not recruiting
Results Published
Start date
01 December 2017
End date
01 October 2023
Chance of happening
100%
Phase
Phase I
Phase II
Design
Blinded
Type
Interventional
Generation
First
Participants
150
Sex
All
Age
18- 60
Therapy
No
Trial Details
This study has two aims: 1) to characterize the effects of intravenous ketamine on neurocognitive markers in depressed patients; 2) to test the efficacy of a synergistic intervention for depression combining intravenous ketamine with neurocognitive training.NCT Number NCT03237286
Sponsors & Collaborators
National Institute of Mental HealthThis company doesn't have a full profile yet, it is linked to a clinical trial.
University of Pittsburgh
This company doesn't have a full profile yet, it is linked to a clinical trial.
Papers
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical TrialThis double-blind, placebo-controlled study (n=154) of ketamine (35mg/70kg) (or placebo) with (and without) positive self-regard training (automated self-association training) finds that the combination can extend the positive antidepressant (MADRS) effects of ketamine, whilst the effects of ketamine alone was not distinguishable from placebo 30 days later.
Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression
This re-analysis of a randomized trial (n=98) investigates the impact of intravenous ketamine on rapidly reversing depression by enhancing neuroplasticity. The study found that greater decreases in mean diffusivity, a marker of microstructural neuroplasticity, from pre-infusion to 24-hour post-infusion were associated with larger improvements in depression scores.
One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression
This follow-up to a randomized clinical trial (n=154) of adults with treatment-resistant depression (TRD) examined the impact of a digital intervention, automated self-association training (ASAT), on prolonging the antidepressant effect of a single ketamine infusion. The trial found that ketamine, followed by four days of ASAT, resulted in a significant effect on depression that lasted for three months, though the benefit was not sustained in months 4 to 12.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.
Quick Inventory of Depressive Symptomatology
The Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR16) is a self-report tool designed to screen for depression and measure changes in the severity of symptoms.